ReviewFrontiers in immunology2026
Glucolipid metabolic dysfunction in ankylosing spondylitis: inflammatory mechanisms, immune-metabolic crosstalk and therapeutic implications of natural products and traditional Chinese medicine.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ankylosing spondylitis (AS) is increasingly recognized as a systemic inflammatory disease accompanied by substantial glucolipid metabolic disturbances and an elevated risk of diabetes. Beyond articular inflammation, persistent immune activation reshapes metabolic homeostasis through interconnected mechanisms involving chronic cytokine signaling, immune-cell metabolic reprogramming, gut microbiota dysbiosis and endocrine disruption. Key mediators, including TNF-α, IL-6 and IL-17, promote insulin resistance, lipid abnormalities and endothelial dysfunction, while Th17/Treg imbalance, neutrophil activation and microbial metabolite alterations further amplify metabolic injury. These pathogenic interactions establish a self-reinforcing cycle in which inflammation and metabolic dysfunction mutually exacerbate one another. Emerging evidence also indicates that anti-inflammatory therapies, nutritional strategies and metabolic modulators may provide dual benefits by controlling disease activity while improving metabolic outcomes. This review summarizes the mechanistic links between AS and glucolipid dysregulation and highlights integrated therapeutic strategies, including pharmacological interventions, nutritional approaches, and natural products/traditional Chinese medicine, for reducing diabetes risk and improving long-term prognosis in AS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.